ME00291B - Postupak kontracepcije i oblik administriranja istog - Google Patents

Postupak kontracepcije i oblik administriranja istog

Info

Publication number
ME00291B
ME00291B MEP-2008-376A MEP37608A ME00291B ME 00291 B ME00291 B ME 00291B ME P37608 A MEP37608 A ME P37608A ME 00291 B ME00291 B ME 00291B
Authority
ME
Montenegro
Prior art keywords
administration
phase
period
uptake
break
Prior art date
Application number
MEP-2008-376A
Other languages
English (en)
French (fr)
Inventor
Hermann Kulmann
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MEP37608A publication Critical patent/MEP37608A/xx
Publication of ME00291B publication Critical patent/ME00291B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Postupak hormonske kontracepcije, u kojem u mnoštvu suštinski vremenski neograničenih, povezanih perioda uzimanja i opciono sa sekvencom koja traje nekoliko godina i u kojoj svaki od slučajeva obuhvata bar jedan ciklus uzimanja sa fazom uzimanja sa konstantnim trajanjem keja traje nekoliko dana u okviru određenog perioda uzimanja i pauzu u uzimanju koja traje nekoliko dana, u kojem se faza ili faze uzimanja po danu administriranja uzima mesto  dnevne jedinice sa bar jednom hormonskom komponentom koja kontraceptivno deluje, kao što su estrogen i/ili gestagen, a u toku pauze ili pauza u uzimanju administriranje zauzima mesto bilo placebo oslobeđen od bilo koje hormonske komponente ili određena pauza u uzimanju koja ostaje u potpunosti oslobođena administriranja a trajanje faze ili faza uzimanja bar konačnog perioda uzimanja traja bar 22 dana,  naznačen time,  što je trajanje faze ili faza uzimanja u bilo kojem periodu uzimanja koji prethodi sledećem periodu uzimanja kraće nego u svakom od siedećih perioda uzimanja, kao i oblik administriranja za hormonsku kontracepciju i posebno njegovo sprcvođenje u delo.
MEP-2008-376A 2000-09-14 2001-09-05 Postupak kontracepcije i oblik administriranja istog ME00291B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045380A DE10045380A1 (de) 2000-09-14 2000-09-14 Verfahren zur Kontrazeption und dessen Darreichungsform
PCT/EP2001/010207 WO2002022110A2 (en) 2000-09-14 2001-09-05 Contraception process and administration form for the same

Publications (2)

Publication Number Publication Date
MEP37608A MEP37608A (en) 2011-02-10
ME00291B true ME00291B (me) 2011-05-10

Family

ID=7656125

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-376A ME00291B (me) 2000-09-14 2001-09-05 Postupak kontracepcije i oblik administriranja istog

Country Status (32)

Country Link
US (2) US8076317B2 (me)
EP (2) EP2153849A3 (me)
JP (3) JP2004508398A (me)
KR (3) KR20090033502A (me)
CN (1) CN100560132C (me)
AR (1) AR030737A1 (me)
AT (1) ATE447972T1 (me)
AU (2) AU2001284052B2 (me)
BG (2) BG107625A (me)
BR (1) BR0113902A (me)
CA (1) CA2420292C (me)
CZ (1) CZ2003723A3 (me)
DE (2) DE10045380A1 (me)
EA (1) EA006875B1 (me)
EE (1) EE200300103A (me)
HK (1) HK1060305A1 (me)
HR (1) HRP20030294A2 (me)
HU (1) HUP0301042A3 (me)
IL (2) IL154521A0 (me)
ME (1) ME00291B (me)
MX (1) MXPA03002070A (me)
NO (1) NO20031152L (me)
NZ (1) NZ524448A (me)
PE (1) PE20020425A1 (me)
PL (1) PL361161A1 (me)
SK (1) SK3102003A3 (me)
TW (1) TWI297271B (me)
UA (1) UA93650C2 (me)
UY (1) UY26932A1 (me)
WO (1) WO2002022110A2 (me)
YU (1) YU19003A (me)
ZA (1) ZA200301359B (me)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
AU2011226911B2 (en) * 2004-04-30 2014-06-19 Bayer Intellectual Property Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026679A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
EP1655031A1 (de) 2004-10-08 2006-05-10 Schering AG Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung
TW200744610A (en) * 2005-06-21 2007-12-16 Organon Nv New regimens for controlled drug delivery devices for contraception
TW200727920A (en) * 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
GB0623813D0 (en) * 2006-11-29 2007-01-10 Stephenson Group Ltd Foam reduction
DE102007011486A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
EP2140860A1 (en) * 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2365103C3 (de) * 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DK0792152T3 (da) * 1994-11-22 2004-07-12 Balance Pharmaceuticals Inc Fremgangsmåder til svangerskabsforebyggelse
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5897539A (en) * 1995-09-28 1999-04-27 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
EP0956024B1 (en) 1996-07-26 2004-07-21 Wyeth Monophasic oral contraceptive method and kit comprising a combination of progestin and estrogen
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy

Also Published As

Publication number Publication date
JP2013006866A (ja) 2013-01-10
KR20030031185A (ko) 2003-04-18
MXPA03002070A (es) 2003-06-24
AR030737A1 (es) 2003-09-03
PE20020425A1 (es) 2002-06-15
EP2153849A2 (en) 2010-02-17
CA2420292C (en) 2010-12-14
EA006875B1 (ru) 2006-04-28
CN1455681A (zh) 2003-11-12
US20120129823A1 (en) 2012-05-24
WO2002022110A3 (en) 2002-07-04
BG111090A (bg) 2012-03-30
TWI297271B (en) 2008-06-01
US20040219174A1 (en) 2004-11-04
HK1060305A1 (en) 2004-08-06
EP2153849A3 (en) 2011-09-14
BG107625A (bg) 2003-11-28
US8536156B2 (en) 2013-09-17
NZ524448A (en) 2005-03-24
NO20031152D0 (no) 2003-03-13
EP1317286B1 (en) 2009-11-11
DE60140462D1 (de) 2009-12-24
ZA200301359B (en) 2004-02-05
DE10045380A1 (de) 2002-04-04
PL361161A1 (en) 2004-09-20
KR20100056577A (ko) 2010-05-27
HRP20030294A2 (en) 2005-02-28
SK3102003A3 (en) 2003-09-11
CN100560132C (zh) 2009-11-18
AU2001284052B2 (en) 2006-11-30
EA200300338A1 (ru) 2003-08-28
WO2002022110A2 (en) 2002-03-21
US8076317B2 (en) 2011-12-13
CZ2003723A3 (cs) 2003-06-18
UY26932A1 (es) 2001-12-28
CA2420292A1 (en) 2002-03-21
UA93650C2 (ru) 2011-03-10
ATE447972T1 (de) 2009-11-15
EE200300103A (et) 2005-02-15
JP2004508398A (ja) 2004-03-18
KR101240232B1 (ko) 2013-03-07
BR0113902A (pt) 2003-07-22
JP2013241456A (ja) 2013-12-05
AU8405201A (en) 2002-03-26
KR20090033502A (ko) 2009-04-03
YU19003A (sh) 2006-05-25
IL154521A0 (en) 2003-09-17
NO20031152L (no) 2003-05-14
EP1317286A2 (en) 2003-06-11
MEP37608A (en) 2011-02-10
IL154521A (en) 2014-05-28
HUP0301042A3 (en) 2010-03-29
HUP0301042A2 (hu) 2003-10-28

Similar Documents

Publication Publication Date Title
ME00291B (me) Postupak kontracepcije i oblik administriranja istog
DK0735882T3 (da) Kombinationsprodukt til kontraception indeholdende progesteronantagonister og gestagen
DK0977554T3 (da) Konfekturesammensætninger
ES2046083B1 (es) Procedimiento para preparar composiciones de liberacion prolongada.
UY26817A1 (es) Agentes antiinflamatorios selectivos de glucocorticoides
HK1076716A1 (en) Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
NO20045117L (no) Fremgangsmate og doseringsformer for kontrollert levering av oksykodon
IL127919A (en) Stabilized pharmaceutical compositions containing bupropion
EA200201000A1 (ru) Гормон-заместительная терапия
CO4700416A1 (es) Composiciones de pantalla solar y metodo para preparar las mismas
NO982902D0 (no) FremgangsmÕte og preparatsett for Õ hindre befruktning hos hunn-pattedyr som omfatter en kombinasjon av gestagen og °strogen
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
PL370450A1 (en) Ginger extract preparation
DK1061929T3 (da) Farmaceutisk præparat på basis af syntetisk naturligt progesteron og östradiol samt fremgangsmåde til fremstilling deraf
NO986104L (no) Progesteron-anti-progesteron regimer
ECSP084358A (es) NUEVAS FORMAS SÓLIDAS DE LA MESOPROGESTINA 11ß-[4E-(HIDROXIIMINOMETIL)-FENIL]- 17ALFA-METOXIMETIL-17ß-METOXI-ESTRA-4,9-DIEN-3-ONA
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
AU3812401A (en) Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver
EP1275379A3 (en) Basic granulate comprising (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
陈联寿 et al. Numerical study on functions affecting tropical cyclone structure and motion
IL110700A (en) Pharmaceutical compositions comprising r (+) isomer of amlodipine
SI1677772T1 (sl) Oralna formulacija antidepresiva, ki obsega acetilsalicilno kislino za pospeĺ evanje nastopa delovanja
WO2003073985A3 (en) New methods of using antiangiogenic agents
Zhang et al. The Effect of Rare Earth Elements on the Kinetics of Boron-Aluminized Layer Growth by Pasty Agent
DK200200624A (da) Polypeptid-præparat